Crimean-Congo hemorrhagic fever virus M-segment nucleic acid vaccine and methods of use and production

A method comprising administering a vaccine comprising a vector comprising a promoter and the nucleic acid of SEQ ID NO:

• 3, the nucleic acid of SEQ ID NO:
• 3 being operably linked to the promoter.

A method of increasing the likelihood of survival or decreasing the likelihood or severity of at least one symptom from a Congo-Crimean Hemorrhagic Fever Virus (CCHFV) in a subject in need thereof, the method comprising administering to the subject a vaccine comprising a vector comprising a promoter and 8.5 μmoles or more of the nucleic acid of SEQ ID NO:

• 1, wherein the nucleic acid of SEQ ID NO:
• 1 is operably linked to the promoter and wherein the administering provides at least a 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.8%, 99.9%, or 100% likelihood of survival in the subject five days after exposure to the CCHFV or the administering reduces the likelihood of a greater than 10% weight loss in the subject after exposure to the CCHFV.

A method of increasing the likelihood of survival or decreasing the likelihood or severity of at least one symptom from a Congo-Crimean Hemorrhagic Fever Virus (CCHFV) in a subject in need thereof, the method comprising administering to the subject a vaccine comprising a vector comprising 8.5 μmoles or more of the nucleic acid of SEQ ID NO:

• 3, and a promoter, wherein the nucleic acid of SEQ ID NO:
• 3 is operably linked to the promoter and wherein the administering provides at least a 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.8%, 99.9%, or 100% likelihood of survival in the subject five days after exposure to the CCHFV or the administering reduces the likelihood of a greater than 10% weight loss in the subject after exposure to the CCHFV.

A method of increasing the likelihood of survival or decreasing the likelihood or severity of at least one symptom from a Congo-Crimean Hemorrhagic Fever Virus (CCHFV) in a subject in need thereof, the method comprising administering to the subject an effective amount of a vaccine comprising a vector comprising a promoter and the nucleic acid of SEQ ID NO:

• 1, wherein the nucleic acid of SEQ ID NO:
• 1 is operably linked to the promoter and wherein the administering provides at least a 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.8%, 99.9%, or 100% likelihood of survival in the subject five days after exposure to the CCHFV or the administering reduces the likelihood of a greater than 10% weight loss in the subject after exposure to the CCHFV.